SUNDAY, FEBRUARY 6
Arrival and Registration

MONDAY, FEBRUARY 7
Welcome and Keynote Session (Joint)
Robert V. Farese Jr., Harvard School of Public Health, USA
and
Tobias Walther, Harvard/HHMI, USA
Dissecting Lipid Droplets: From Mechanisms to New Therapies

Adipose Tissue Crosstalk in Metabolic Diseases (Joint)
Camilla Charlotte Schéele, University of Copenhagen, Denmark
BATokines
Yu-Hua Tseng, Joslin Diabetes Center/Harvard Medical School, USA
Lipokines Driving Thermogenesis
Edward T. Chouchani, Dana-Farber Cancer Institute, USA
Succinate Regulation of Metabolism

Short Talk(s) Chosen from Abstracts

Workshop 1: Industry Clinical Trials in NASH (Q1)
*Saswata Talukdar, Merck, USA

Short Talks Chosen from Abstracts

Endocrine Factors as Therapeutic Targets in NASH (Q1)
Lotte Bjerre Knudsen, Novo Nordisk A/S, Denmark
GLP 1 Receptor Agonists: Mechanisms Relevant for the Treatment of NASH
Greg Steinberg, McMaster University, Canada
Endocrine Factors in NASH
Katrin J. Svensson, Stanford University, USA
Novel Secreted Factors Regulating Metabolism

Short Talk(s) Chosen from Abstracts

Factors the Improve Fat Function, but not Mass (Q2)
Ruth J.F. Loos, Mount Sinai School of Medicine, USA
Genetics Uncoupling Obesity from Metabolic Complications
Jacqueline M. Stephens, Louisiana State University, USA
Pathways that Modulate Adipocyte Function and Improve Systemic Metabolic Function
Andrew J. Whittle, Novo Nordisk, USA
Obesity Research

Short Talk(s) Chosen from Abstracts

TUESDAY, FEBRUARY 8
Inflammation, Fibrosis and the Gut Microbiome (Q1)
Ido Amit, Weizmann Institute, Israel
Lipid Associated Macrophages and TREM2
Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Hepatic Stellate Cells and Liver Fibrosis
Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA
Role of the Gut Microbiome as a Biomarker and Therapeutic Target in NASH

Nuts and Bolts of Adipocyte Biology (Q2)
Ursula A. White, Pennington Biomedical Research Center, USA
Unbiased Proteomics to Discover Biomarkers and Therapeutic Targets in NASH
Takanori Takebe, Cincinnati Children’s Hospital Medical Center, Japan
Modeling Steatohepatitis in Humans with Liver Organoids

Short Talk(s) Chosen from Abstracts

Emerging Technologies for the Study of Tissue Crosstalk (Q1)
Natalie Krahmer, Helmholtz Zentrum München, Germany
Unbiased Proteomics to Discover Biomarkers and Therapeutic Targets in NASH
Takanori Takebe, Cincinnati Children’s Hospital Medical Center, Japan
Modeling Steatohepatitis in Humans with Liver Organoids

Speaker to be Announced
Short Talk(s) Chosen from Abstracts

Workshop 2 (Q1)

Short Talks Chosen from Abstracts

Muscle-Liver Cross-Talk (Q1)
Matthew Watt, University of Melbourne, Australia
Hepatokines Regulating Muscle Metabolism
Bente Klarlund Pedersen, University of Copenhagen, Denmark
Muscle-organ Cross-Talk – Focus on IL-6
Isabelle Leclercq, Université catholique de Louvain, Belgium
Sarcopenic Obesity and NASH

Short Talk(s) Chosen from Abstracts

* Session Chair † Invited but not yet accepted  Program current as of September 22, 2021. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.
Influences of Adipose Tissue Immune Cells (Q2)
- Myriam Aouadi, Karolinska Institutet, Sweden
  *Macrophages Influence on Metabolism beyond Inflammation*

- Vishwa Deep Dixit, Yale University, USA
  *Aging and Adipose Tissue inflammation*

- Alyssa H. Hasty, Vanderbilt University, USA
  *Iron Metabolism and AT Macrophages*

Short Talk(s) Chosen from Abstracts

Poster Session 2

**WEDNESDAY, FEBRUARY 9**

**NASH Therapeutics (Q1)**
- Mary E. Rinella, Northwestern University, USA
  *Recent Advances of Defining Endpoints in NASH Clinical Trials*

- Sophie Bozec, Poxel SA, France
  *PXL770 a Direct AMPK Activator for the Treatment of NASH*

- Saswata Talukdar, Merck, USA
  *New Advances in NASH Therapies*

Short Talk(s) Chosen from Abstracts

**Alternate Models of Disease and Metabolism (Q2)**
- Jennifer Watts, Washington State University, USA
  *Using C. elegans to Study Lipid Synthesis and Function*

- Fiona Oakley, Newcastle University, UK
  *Bioreactor Technology for Modeling Fibrosis in Human and Rodent Liver*

- Marcel den Hoed, Uppsala University, Sweden
  *Using Zebrafish Larvae to Characterize Candidate Genes for Cardiometabolic Health*

Short Talk(s) Chosen from Abstracts

**Workshop 3 (Q1)**

Short Talks Chosen from Abstracts

**Genetics and Liver Derived Signaling Molecules (Q1)**
- Yaron Rotman, NIDDK, National Institutes of Health, USA
  *Genetic Regulation of Liver Lipid Metabolism*

- Chen-Yu Zhang, Nanjing University, China
  *Liver-Islet Communication: Role of miRNAs*

- Anna Mae Diehl, Duke University, USA
  *Novel Liver Derived Cytokines*

Short Talk(s) Chosen from Abstracts

**Adipose Tissue Microenvironment: Fibrosis/Extracellular Matrix Remodeling (Q2)**

Karine Clément, INSERM / Sorbonne Universite, France
*Human Adipose Tissue Fibrosis*

Antonio J. Vidal-Puig, University of Cambridge, UK
*Uncoupling of Adipose Tissue Fibrosis from Inflammation*

Silvia Corvera, University of Massachusetts Medical School, USA
*Adipose Tissue Angiogenesis*

Short Talk(s) Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Q1)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Q2)

**THURSDAY, FEBRUARY 10**

Departure